Effects of Autologous Blood Injection Versus Platelet Rich Plasma on Chronic Plantar Fasciitis

Is There Any Advantage of PRP Over Autologous Blood Injection in the Treatment of Chronic Plantar Fasciitis? A Prospective Randomized Double Blinded Study

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05240872

Acronym

PF:AutovsPRP

Enrollment

Registered

2022-02-15

Start date

2020-03-01

Completion date

2022-01-15

Last updated

2022-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar Fascitis

Keywords

heel pain, platelet rich plasm, autologous blood injection

Brief summary

To explore effects of Autologous Blood Injection versus Platelet Rich plasma injection for treatment of chronic plantar fasciitis

Detailed description

After clinical diagnosis of patients with plantar fasciitis. Patients were divided into two groups. Group A (PRP injection group) and Group B (ABI group) were randomized according to web based block group randomization. Patients were evaluated prior to injection in terms of Health related quality of life scores related to foot and ankle diseases (AOFAS and FADI) and VAS. After injection at 1st, 3rd and 6th months HRQoL were compared between groups. Intra group evaluation for HRQoL were performed at f/up visits. Independent t test and repeated measure ANOVA test used for statistical analysis

Interventions

BIOLOGICALPRP injection

Plantar fascia injection therapy with PRP

BIOLOGICALABI injection

ABI injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Participants who were diagnosed with chronic plantar fasciitis 2. Nonresponded to o conservative treatment (stretching exercises, nonsteroidal anti-inflammatory drugs, and heel pads) for at least 6 weeks 3. Patient should be able to understand the informed consent about type of treatment and blindness and randomization 4. Visual analog scale pain higher than 5 (on a 10-point visual analog scale)

Exclusion criteria

1. previous history of any type of local injection treatment for heel pain 2. history of surgery for heel pain, foot and ankle disorders, fractures 3. Associated pathology involving the lower limb such as * tarsal tunnel syndrome * effusion of the ankle indicating an intra-articular disease * Peroneal/Achilles/tibialis tendons pathology * any obvious deformity of foot and ankle, 4. Patients with systemic disorder like diabetes mellitus, ankylosing spondylitis rheumatoid arthritis, hematological disease, or gout 5. Pregnancy 6. Use of antiocoagulation -

Design outcomes

Primary

Measure	Time frame	Description
Changes in Visual Analogue Scale (VAS)	0,1 st 3rd and 6th month; changes between time points will be assessed	Visual Analogue Scale 10 worst 0-1 best in terms of pain outcome
Changes in American Orthopaedic Foot & Ankle Society (AOFAS ) Score	0,1 st 3rd and 6th month; changes between time points will be assessed	American Orthopaedic Foot & Ankle Society (AOFAS) Clinical rating systems for the ankle-hindfoot, midfoot, hallux, and lesser toes Evaluation:0 worst 100 best
Changes in Foot and Ankle Disability Index (FADI)	0,1 st 3rd and 6th month; changes between time points will be assessed	Foot and Ankle Disability Index Evaluation:0 worst 100 best

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026